Melden Sie sich an, um zu speichern und Updates zu erhalten.
How might the discovery of plasma biomarkers for Alzheimer's in middle-aged people affect health policies and community support programs?
Alzheimer's disease has a long preclinical phase in which neuropathological changes, such as amyloid β (Aβ) and tau pathology, accumulate over many years.1 This preclinical phase provides an opportunity for earlier disease detection and interventions to prevent or delay dementia. Emerging blood-based biomarkers provide a minimally invasive approach to assess Alzheimer's disease-related pathology and show promising diagnostic and prognostic value in symptomatic individuals.2 However, performance of these biomarkers in cognitively unimpaired, middle-aged populations remains unclear
Quellartikel
The Lancet (United Kingdom) | May 30, 2026
The Lancet (United Kingdom) | May 30, 2026
The Lancet (United Kingdom) | May 30, 2026
El País English (Spain) | May 29, 2026
Your votes count
No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.
Übersetzung ausstehend
Übersetzung ausstehend
💡 How This Works
- • Add Statements: Post claims or questions (10-500 characters)
- • Vote: Agree, Disagree, or Unsure on each statement
- • Respond: Add detailed pro/con responses with evidence
- • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement
Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.
Support us